Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders
about
The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's diseaseEvidence for the use of pimavanserin in the treatment of Parkinson's disease psychosisElucidating the role of neurotensin in the pathophysiology and management of major mental disorders.New small molecules for the treatment of Parkinson's disease.Classics in Chemical Neuroscience: Aripiprazole.Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers.Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Aporphinoid antagonists of 5-HT2A receptors: further evaluation of ring A substituents and the size of ring C.Pimavanserin for the treatment of Parkinson's disease psychosis.Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response modelMolecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligandsManaging insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon.Emerging drugs for insomnia: new frontiers for old and novel targets.High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens.Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death.Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication.Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation.New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges.Serotonin 2A receptor antagonists for treatment of schizophrenia.Role of 5-HT2A receptor antagonists in the treatment of insomnia.Potential serotonergic agents for the treatment of schizophrenia.Current Understanding of Psychosis in Parkinson's Disease.Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases.Atypical antipsychotics and inverse agonism at 5-HT2 receptors.Discovery of potential antipsychotic agents possessing pro-cognitive properties.Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.Investigation of metabolic profile of pimavanserin in rats by ultrahigh-performance liquid chromatography combined with Fourier transform ion cyclotron resonance mass spectrometry.Development of a UPLC-MS/MS method for determination of pimavanserin tartrate in rat plasma: Application to a pharmacokinetic study.Direct radiofluorination of [18F]MH.MZ for 5-HT2A receptor molecular imaging with PETPathological Conditions Associated with the Disturbance of the 5-HT System
P2860
Q26745661-D3AC32A8-1236-4F00-AFBA-F4DD39BA0D9EQ28074468-D8FAC0D0-8A8B-412B-B850-0CDDE896F217Q30426586-9F9E060C-B61B-441D-BEC4-9A67DB5EF483Q33636631-04A26981-4AD1-48AE-91EF-FDD085090BB1Q33866125-34A63CCD-01AD-4E19-8857-7E26347EE881Q34025072-BF04DB3E-D377-49D1-B0E9-7E3129DBD3EDQ34169978-84ECCE95-2B98-4DAC-91F2-74261B9F02D1Q34274859-73ADF492-0105-40AE-A91D-FB771456A804Q34339077-CF997373-71DA-4B1D-95FC-FA8FCCCB7C8EQ34369646-FF5F4333-A348-4D04-BE0C-42BEB6C1F328Q37125668-5FCDF06E-3CA9-441F-AE9A-F3A8728D85EBQ37331831-994545CF-42BC-478D-BABE-13BB3F67B295Q37450164-2D7D906D-95E8-4036-B69E-3B3DF11181CCQ37587178-3475A648-9FA4-443E-94A3-C9E22D8A79F0Q37630040-0C58B673-886E-415F-8E91-5BCFE2CA1D60Q37672302-94B94724-42DC-4C1F-B4E6-D803C83169FCQ37728569-37211A9A-BC34-49F9-B79E-291DAA79633AQ37834732-1003B432-B455-4E0F-9628-1C2739579494Q37853032-9909FB79-E13E-4884-851F-08D916C36FC5Q37899193-1FCFB207-644E-42B3-9B81-BD5366C7F0C3Q38101551-7F7B7D45-BCCE-4CEE-AFB0-5512F408BE66Q38635792-78D2F310-2929-4E43-9D74-750B8DE80FF5Q38954642-0C5700E9-107D-42B2-8FBB-AEF1F47EF1F3Q38998475-2334B877-9E87-4CD9-B3AA-B4F902EBC330Q41250110-F51A1FCF-1728-46C4-9B7E-91BB03CA5F8CQ42803307-1DE14DE9-A0B4-4423-8778-B1225F9B01A6Q43375910-DFD685F4-C0CA-4CC1-9652-9DBFA71B842CQ48360606-3CC92C60-B743-4AD0-B67E-ABBF7F4A6747Q49200036-A27EA052-933E-488E-B069-015551FA0F85Q53010429-340B56EA-5960-4CA1-98C3-92624B2976F7Q59201274-7A51B009-548E-4EC6-B887-2EFABD795CA1
P2860
Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Pimavanserin tartrate: a 5-HT2 ...... ous neuropsychiatric disorders
@ast
Pimavanserin tartrate: a 5-HT2 ...... ous neuropsychiatric disorders
@en
Pimavanserin tartrate: a 5-HT2 ...... ous neuropsychiatric disorders
@nl
type
label
Pimavanserin tartrate: a 5-HT2 ...... ous neuropsychiatric disorders
@ast
Pimavanserin tartrate: a 5-HT2 ...... ous neuropsychiatric disorders
@en
Pimavanserin tartrate: a 5-HT2 ...... ous neuropsychiatric disorders
@nl
prefLabel
Pimavanserin tartrate: a 5-HT2 ...... ous neuropsychiatric disorders
@ast
Pimavanserin tartrate: a 5-HT2 ...... ous neuropsychiatric disorders
@en
Pimavanserin tartrate: a 5-HT2 ...... ous neuropsychiatric disorders
@nl
P2860
P921
P1476
Pimavanserin tartrate: a 5-HT2 ...... ous neuropsychiatric disorders
@en
P2093
Atheir Abbas
Bryan L Roth
P2860
P304
P356
10.1517/14656560802532707
P407
P577
2008-12-01T00:00:00Z